Indian Pharmas Seen Ripe For Domestic Consolidation
This article was originally published in PharmAsia News
Some pharmaceutical industry experts in India see recent tries to acquire Orchid Pharmaceuticals and Dabur Pharma as indicative of a new consolidation move in India. In the past, the industry has spurned consolidation on grounds it has 20,000 members able to market in India. But experts see a dwindling share of that market by Indian companies driving a merger move by many. One industry leader said consolidation would improve efficiency and increase production capacity while preventing facility duplication. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.